Ferguson BS, Rogatzki MJ, Goodwin ML, Kane DA, Rightmire Z, Gladden LB
Cluster 0 was identified as inflammatory fibroblasts with high expressions of Cxcl12 and Cxcl13
Comparative Advantage: DSIP may improve sleep quality without significant REM suppression or next-day cognitive impairment, differing from conventional hypnotics and sedatives
Overall, rFGF21 treatment decreased the AFG3L2-mediated degradation of SLC25A39 and facilitated the import of mitochondrial GSH
CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
In obese rodent models, it promotes lipolysis by breaking down stored fats into free fatty acids without stimulating GH pathways such as IGF-1